Video

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03

Author(s):

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD, reviews updated data comparing trastuzumab deruxtecan versus trastuzumab emtansine for the treatment of HER2+ metastatic breast cancer.

Related Videos
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
Related Content
Kari Wisinski, MD, the Endowed Professor of Hematology and Oncology and chief of the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison
November 12th 2024

Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
November 7th 2024

AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Jo Chien, MD
November 4th 2024

Lasofoxifene Suppresses Ki-67 Expression in HR+/HER2– Early-Stage Breast Cancer